Abnormal gene expression patterns are often implicated in the development of different 57 diseases, and thus, detailed insights into the underlying mechanisms of gene regulation will be 58 fundamental in identifying novel interventional treatment strategies. Enormous progress over 59 the last few years, particularly in the field of epigenetic regulation, has contributed to a better 60 understanding of how gene activity is controlled. 61
In the nucleus DNA is packaged with histones and non-histone proteins in a dynamic 62 structure called chromatin. The grade of chromatin compaction can influence DNA 63 accessibility to the transcriptional machinery. Euchromatin is loosely packed and 64 transcriptionally active, whereas heterochromatin represents a more densely packed chromatin 65 state which is characterized by low transcriptional activity. Heterochromatin can be 66 subdivided into two categories: facultative heterochromatin for silencing of developmental 67 genes and the inactive X chromosome in female mammals, and constitutive heterochromatin 68 which is formed at pericentromeric regions and telomeres. 69 Facultative heterochromatin is marked by high levels of H3K27me3 (86). In contrast, 105 constitutive heterochromatin features the combinatorial mark H3K9me3 and H4K20me3 (52). 106
The enzymatic systems for many chromatin-modifying activities have been identified during 107 the last years, however, still very little is known about their targeting to specific genomic 108 regions. For gene silencing and heterochromatin formation across repetitive elements, the 109 production of distinct types of non-coding RNA, antisense RNA and small interfering RNA 110 (siRNA), has been implicated in the targeting mechanism. 111
In mammals, the promoter regions of many genes are transcribed at a low level, giving rise to 112 promoter-associated RNAs (30 In healthy individuals up to 100 tandem copies of the D4Z4 element generate a 172 heterochromatic domain that silences the nearby genes ( Figure 2A ). FSHD patients have less 173 D4Z4 repeats (1-10 copies) (89). Interestingly, smaller D4Z4 arrays result in earlier disease 174 onset and enhanced severity in patients (74, 85, 97) . Genes proximal to D4Z4 are often 175 inappropriately overexpressed in FSHD patients (24) 
Silencing of FRG1 is dependent on heterochromatic histone methylation marks 193
The close proximity to D4Z4 repeats and the dependence on the repeat number suggest that 194 In summary, the data suggest that FSHD is connected to epigenetic dysregulation of D4Z4 234 repeats, however, at the current stage of analysis it is not possible to build a consistent model. 235
In future studies it will be crucial to analyze a broader spectrum of epigenetic modifications 236 across the entire 4q35 region. Furthermore it would be very helpful to put these data in 237 context with expression analyses of not only FRG1 but also all other genes in this locus. It is 238 very likely that FRG1 overexpression only correlates with a subset of FSHD patients and 239
other genes might also contribute to disease development. Before specific disease treatment 240 strategies can be developed, the phenotypic FSHD subtypes need to be much better defined on 241 the molecular level. 242 243
Triplet repeat induced heterochromatin formation in Friedreich's Ataxia 244
In the previous section we discussed a disease which is caused by reduced heterochromatin 245 silencing. However, there are also human diseases which can be linked to ectopic 246 heterochromatin formation and aberrant gene silencing. In this section we will describe how 247 repetitive expansion of small nucleotide stretches, often triplets, in promoter, intron or exon 248 regions can lead to heterochromatin formation and silencing of the associated gene, resulting 249 in the development of a disease (59 Healthy individuals carry between 6 and 36 GAA repeats in intron 1 of frataxin ( Figure 3A) , 261 while FRDA patients show expansions ranging from 120-1700 repeats (10, 15, 18, 61 Another intriguing possibility to explain heterochromatin formation is antisense transcription 302 across the FXN locus ( Figure 3B ). In S. pombe bidirectional transcription generates double 303 stranded RNA which is processed by the RNAi machinery and can induce heterochromatin 304 formation across the underlying genomic locus (29). Thus, production of the FAST-1 305 transcript could be crucial for the silencing mechanism in FRDA. Furthermore there is 306 evidence for antisense transcription in other repeat expansion diseases (13, 53), indicating that 307 this process may be of general importance. A major regulator for antisense transcript 308 production might be CTCF. In FRDA patients, loss of CTCF binding correlates with 309 accumulation of FAST-1 transcripts, and also in a related disease, myotonic dystrophy type 1 310 (DM1), CTCF limits antisense transcription (13). Further analyses are required to demonstrate 311 whether CTCF directly functions in transcriptional control at these loci.
A third model for induction of heterochromatin at trinucleotide repeat loci was suggested 313 recently (48) and might play a role in distinct repeat expansion diseases ( Figure 3B) . 314
Transcripts containing expansions of CAG or CUG repeats, as found in fragile X syndrome 315 (FXS) and DM1, can form stable hairpin loops that are substrates for dicer (48). Reduced 316 transcript levels can be explained by dicer-mediated cleavage of the primary transcripts, 317 leading to lower production of mature RNA. In analogy to siRNA triggered formation of 318 heterochromatin, cleavage products of CNG hairpins might resemble siRNAs that potentially 319 trigger heterochromatin formation using a similar mechanism. 320 Therapeutic strategies for repeat expansion diseases have focused on the development of 321 treatments to minimize the adverse effects of missing an important gene. Mitochondrial 322 dysfunction in FRDA, for example, benefits from an antioxidant therapy. Over the last years it 323 has become clear that frataxin is silenced by local heterochromatin. This has led, more 324 recently, to novel therapeutic strategies being developed which impair heterochromatin 325 formation to allow higher expression of frataxin. This class of therapeutics, histone 326 deacetylase inhibitors, is very promising as frataxin levels could be increased in FRDA 327 patient cells (34) and in a mouse model (73). However, global dysregulation of histone 328 deacetylation might cause severe side effects. Only a better molecular understanding of the 329 epigenetic machinery that specifically targets repeat expansion loci will help to ultimately 330 develop specific compounds for treatment of this class of diseases. 331 332
Epigenetic dysregulation of imprinting control regions in Prader-Willi Syndrome and 333

Angelman Syndrome 334
Heterochromatin at regulatory elements can affect transcription of many genes in a large 335 genomic domain. In this section we discuss diseases which are caused by genetic or 336 epigenetic dysregulation at such regulatory regions. 337
Genomic imprinting is a mechanism to establish allele-specific differences in gene expression 338 dependent on the parental origin (37). 
Local heterochromatin formation at the maternal PWS-ICR 374
How are these allele-specific expression patterns established? The AS-ICR seems central to 375 induce silencing of the maternal PWS-ICR during development (40, 69), however, it might 376 not be involved in direct transcriptional control of the 15q11-13 region which is rather 377 regulated by the PWS-ICR. On the paternal allele, PWS-ICR carries active epigenetic 378 modifications, i.e. H3K4 methylation (98) and absence of DNA methylation (20, 25) . This 379 stimulates transcription in cis across the entire 15q11-13 region. Notably, in this case UBE3A 380 is transcribed in the antisense direction, which may inhibit the production of sense transcript, 381
and is hypothesized to keep this gene silent on the paternal chromosome (76). On the maternal 382 allele, however, the PWS-ICR features heterochromatic modifications, such as H3K9me3, 383
H4K20me3 and DNA methylation (20, 25, 96, 98) . Genes in the 15q11-13 region are 384 consequently silenced by DNA methylation in their promoter regions. The UBE3A gene can 385 be transcribed from the maternal allele as there is no more antisense transcription (Figure 4) . 
Stability of allele-specific expression patterns in imprinting diseases 405
How can defective imprinting on only one allele generate severe diseases as, e.g. Angelman 406
Syndrome and Prader-Willi Syndrome? In AS patients, if the AS-ICR is maternally impaired 407 repressive heterochromatin cannot be established on the PWS-ICR (Figure 4 ). This leads to 408 aberrant activation of the PWS-ICR on the maternal chromosome which prevents proper 409 sense transcription of UBE3A (76). In PWS patients, deletion or impairment of the paternal 410 PWS-ICR which would normally carry active modifications, prevents transcriptional activity 411 across the entire 15q11-13 region on the paternal chromosome (55). Notably, all these genes 412 are potentially functional on the maternal chromosome, however, they cannot be expressed 413 due to repressive histone modifications at the maternal PWS-ICR (Figure 4 ). An intriguing 414 possibility to treat this imprinting disease would be to reactivate these silenced alleles. 415
Apparently, specific DNA elements in the PWS/AS ICR are necessary to maintain the allelic 416 imprint by recruiting regulatory proteins which are involved in targeting epigenetic 417 machineries (41). A detailed mechanistic knowledge of these mechanisms is required to 418 develop specific treatment strategies. However, a balanced treatment with general inhibitors 419 of DNA methylation (77) Enormous progress over the last years has improved our understanding of how epigenetic 507 mechanisms contribute to the development of human diseases. These efforts already led to the 508 development of novel therapeutic strategies, which, however, may have side effects. In order 509
to refine these strategies, we need to better understand the interplay between the epigenetic 510 machineries, and we need to learn more about selective targeting mechanisms. Regarding 511 heterochromatin mediated gene silencing, there is evidence from Drosophila that different 512 In order to identify such pathways, a consistent and systematic analysis of epigenetic 518 modifications and transcriptional regulation in healthy vs. patient material is required. 519
Identification of epigenetic machineries that work in the context of a specific disease-related 520 locus is only the first step. The next question is how these machineries are targeted. Do these 521 epigenetic enzymes interact with proteins that recognize a specific DNA sequence and could 522 an inhibitor for this interaction prevent targeting? Recent data suggest that a different 523 mechanism, binding of non-coding RNAs, assist in targeting. If we understand how the 524 production of these RNAs is controlled we might get novel tools for regulating site-specific 525 targeting of epigenetic modifications (33, 64) . Reagents that mediate degradation of these 526 ncRNAs, e.g., antisense RNAs, might allow specific reactivation of aberrantly silenced genes, 527 such as frataxin in FRDA or tumor suppressor genes in cancer. 528
In this review we discuss how heterochromatin dysregulation can generate severe disease 529 phenotypes. Much less is known about smaller changes in epigenetic programming that would 530 not necessarily cause pathological effects. We hypothesize that during aging, stochastic errors 531 in establishing or maintaining epigenetic programming occur during DNA damage repair 532 (66), or can be triggered by environmental factors. Accumulation of this epigenetic damage 533 may then contribute to the systemic aging phenotype. Treatment strategies that aim toward 534 correcting epigenetic programming in human diseases may also be useful to treat the adverse 535 effects of aging. 536 537
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